Trial Profile
A Multi-Center, Double-Blind, Vehicle Controlled, Phase II Study of JNJ 10229570-AAA for the Treatment of Acne Vulgaris
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Oct 2019
Price :
$35
*
At a glance
- Drugs JNJ 10229570 AAA (Primary)
- Indications Acne vulgaris
- Focus Therapeutic Use
- Sponsors Bausch Health Companies; Valeant Pharmaceuticals International
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
- 22 Apr 2014 New trial record